PROMETH FORTIS Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Prometh Fortis, and when can generic versions of Prometh Fortis launch?
Prometh Fortis is a drug marketed by Alpharma Us Pharms and is included in one NDA.
The generic ingredient in PROMETH FORTIS is promethazine hydrochloride. There are twelve drug master file entries for this compound. Fifty suppliers are listed for this compound. Additional details are available on the promethazine hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Prometh Fortis
A generic version of PROMETH FORTIS was approved as promethazine hydrochloride by ZYDUS PHARMS USA on November 18th, 2005.
Summary for PROMETH FORTIS
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 123 |
Patent Applications: | 2,654 |
Formulation / Manufacturing: | see details |
DailyMed Link: | PROMETH FORTIS at DailyMed |
Anatomical Therapeutic Chemical (ATC) Classes for PROMETH FORTIS
US Patents and Regulatory Information for PROMETH FORTIS
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Alpharma Us Pharms | PROMETH FORTIS | promethazine hydrochloride | SYRUP;ORAL | 084772-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |